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Abstract
Background: Dementia is a progressive disease that decreases quality of life of persons with dementia and is
associated with high societal costs. The burden of caring for persons with dementia also decreases the quality of
life of family caregivers. The objective of this study was to assess the societal cost-effectiveness of Namaste Care
Family program in comparison with usual care in nursing home residents with advanced dementia.
Methods: Nursing homes were randomized to either Namaste Care Family program or usual care. Outcome
measures of the cluster-randomized trial in 231 residents included Quality of Life in Late-Stage Dementia (QUALID)
and the Gain in Alzheimer Care Instrument (GAIN) for family caregivers over 12 months of follow-up. Health states
were measured using the EQ-5D-3L questionnaire which were translated into utilities. QALYs were calculated by
multiplying the amount of time a participant spent in a specific health state with the utility score associated with
that health state. Healthcare utilization costs were estimated using standard unit costs, while intervention costs
were estimated using a bottom-up approach. Missing cost and effect data were imputed using multiple imputation.
Bootstrapped multilevel models were used after multiple imputation. Cost-effectiveness acceptability curves were
estimated.
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Results: The Namaste Care Family program was more effective than usual care in terms of QUALID (− 0.062, 95%CI:
− 0.40 to 0.28), QALY (0.0017, 95%CI: − 0.059 to 0.063) and GAIN (0.075, 95%CI: − 0.20 to 0.35). Total societal costs
were lower for the Namaste Care Family program as compared to usual care (− 552 €, 95%CI: − 2920 to 1903).
However, these differences were not statistically significant. The probability of cost-effectiveness at a ceiling ratio of
0 €/unit of effect extra was 0.70 for the QUALID, QALY and GAIN.
Conclusions: The Namaste Care Family program is dominant over usual care and, thus, cost-effective, although
statistical uncertainty was considerable.
Trial registration: Netherlands Trial Register (http://www.trialregister.nl/trialreg/index.asp, identifier: NL5570, date of
registration: 2016/03/23).
Keywords: Dementia, Quality of life, Namaste care, Cluster randomized controlled trial, Family caregiving, Person-
centered care, Palliative care, Nursing home, Cost-benefit analysis
Background
Worldwide, 50 million people live with dementia. Total es-
timated costs caused by dementia were $948 billion in 2016
with Europe and North-America experiencing the highest
economic burden [1]. Because of the progressive nature of
dementia, quality of life in people with dementia and their
family members is severely affected [2–5]. There are several
psychosocial interventions available for people with demen-
tia, but there are not many interventions that specifically
target people with advanced dementia [6]. Moreover, psy-
chosocial interventions are generally not part of end-of-life
care. However, there is evidence that appropriate end-of-
life care in advanced dementia effectively addresses patients’
and families’ concerns and needs [7].
People with advanced dementia are often admitted to
long-term care facilities. Although care in such facilities is
primarily taken over by professionals, the burden for family
caregivers (i.e. family, relatives, friends) often remains high
[8]. In addition, family caregivers sometimes find it difficult
to sustain a meaningful connection with people with ad-
vanced dementia with decreased communication skills. Fam-
ily caregivers may be frustrated, especially if possibilities for
verbal communication are limited due to for example apha-
sia. As a result, visits might be experienced as stressful [9].
Existing psychosocial interventions for people with dementia
living in long-term care facilities usually do not include fam-
ily caregivers. Moreover, effects of such interventions on
family caregiver experiences are generally not evaluated.
Namaste Care is a psychosocial intervention for people
with advanced dementia that entails person-centered care
for people with advanced dementia involving nursing staff
and volunteers [10]. The primary aim of the program is to
improve the quality of life of people with advanced de-
mentia by focusing on a meaningful connection with
them, which might result in positive effects in people with
dementia and their family caregivers. Studies reported that
Namaste Care successfully improves the quality of life of
people with advanced dementia and their family caregivers
without extra healthcare costs [11–13]. Despite the fact
that these studies have estimated costs and effects associ-
ated with Namaste Care, no full economic evaluation has
been performed yet. Furthermore, Namaste Care reduced
behavioral symptoms of dementia as well as the use of
psychotropic medication [14–16]. However, the aforemen-
tioned studies primarily focused on the qualitative (i.e.
subjective) aspect of Namaste Care. So far, no randomized
controlled trials have been performed that assessed the
(cost-) effectiveness of Namaste Care. Therefore, the aim
was to assess the cost-effectiveness of an adapted version
of Namaste Care, the Namaste Care Family program, in
comparison with usual care among people with advanced
dementia and their family caregivers.
Methods
Study design
The economic evaluation was conducted from a societal
perspective alongside a cluster-randomized controlled
trial that compared the Namaste Care Family program
with usual care over a time horizon of 12 months. The
protocol was evaluated by the Medical Ethics Review
Committee of the VU University Medical Center in
Amsterdam, the Netherlands (protocol number:
2016.399) and is registered in the Netherlands Trial
Register (http://www.trialregister.nl/trialreg/index.asp,
identifier: NL5570). The committee declared that no fur-
ther formal review was needed, since the study was de-
clared exempt from the scope of the Medical Research
Involving Human Subjects Act. Detailed information on
the study design and the Namaste Care Family program
trial is provided elsewhere [17]. Funding sources were
not involved in the design and execution of the study or
writing of the study results.
Recruitment and setting
Nineteen Dutch nursing homes with a psychogeriatric
ward were recruited. Dutch nursing homes offer long-
term care, some in a domestic-small-scale living style
environment. It includes 24-h functional support and
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(medical and nursing) care for people that are in need of
assistance with activities of daily living.
Randomization and sample size
Participating nursing homes were matched on several
characteristics that potentially affect the outcomes.
These characteristics were collected by means of a ques-
tionnaire sent out to the managers of the nursing homes
and included questions on the number of beds, whether
the nursing home offered small-scale living arrange-
ments for persons with dementia yes or no, whether it
was situated in a rural or urban area, and the number of
offered psychosocial programs such as “Snoozelen”. Fur-
thermore, the religious orientation of the nursing home
was also used as a matching criterion when it was felt it
affected end-of-life decision-making care practice. Pos-
sible matches were judged by three researchers (HJAS,
KJJ and JTvdS). Subsequently, matched pairs of nursing
homes were randomized by an independent statistician.
Due to the nature of the intervention, the group alloca-
tion could not be masked. Sample size calculations indi-
cated that with 192 participants, power sufficed to detect
a relevant difference in participants’ quality of life [17].
Recruitment of participants
Within each nursing home, nursing staff was asked to
indicate potentially eligible residents. Residents were eli-
gible if they had advanced dementia and were unable to
participate in regular activity programs, or if they had
moderate dementia with behavioral symptoms of de-
mentia such as agitation, aberrant motor behavior, ag-
gression or apathy. If the nursing staff was of the
opinion that the resident or family caregiver could bene-
fit from the program, for example because the resident
was responsive to touch, the resident was considered eli-
gible. Further, eligible residents had family caregivers
with sufficient proficiency in Dutch who were willing
and able to fill in questionnaires. Written informed con-
sent was provided by family caregivers. No financial in-
centive to participate was provided.
Ultimately, nineteen nursing homes consented to par-
ticipate and were allocated to the Namaste Care Family
program (n = 10) or usual care (n = 9).
Intervention
Namaste Care is a multidimensional care program with
psychosocial, sensory and spiritual components that in-
corporates tailored and personalized care until death for
people with advanced dementia. Experiences and out-
comes of family caregivers may be improved when their
involvement in the program is increased. Hence, we ex-
panded the program by also inviting family caregivers to
training sessions and involve them in Namaste Care,
which is referred to as the Namaste Care Family
program [10]. Ideally, this Namaste Care Family pro-
gram was given 7-days-a-week in two 2-h sessions [10].
The sessions took place in a calm room with a ‘home-
like’, relaxed setting, the so-called ‘Namaste-room’. In
this ‘Namaste-room’, pleasant scents were used and na-
ture sounds or soft music were played. Furthermore, at-
tempts were made to avoid external distractions or
interruptions. Each session started with personally wel-
coming each participant when entering the Namaste-
room. Each participant was comfortably seated and
screened for signs of pain. Appetizing, nutritious foods
and drinks were offered frequently. The main aim was to
establish a meaningful connection between participants
and family caregivers. Extra personal care (e.g. massages,
grooming, nail care and washing the face, hands and
feet) was offered during the sessions to aid in an experi-
ence of a gentle, caring touch. Each session ended with
nursing staff personally thanking each participant for at-
tending the session. A more detailed description of the
intervention can be found elsewhere [17]. In the control
group, participants only received usual care, which was
not restricted in any way.
Clinical outcomes
Data were collected between May 2016 and December
2018. Primary clinical outcomes were the Quality of Life
in Late-Stage Dementia (QUALID) [18], the three-level
version of the EuroQol (EQ-5D-3L) [19], and the Gain
in Alzheimer Care Instrument (GAIN) [20], which were
assessed at baseline, and 1, 3, 6 and 12months after
baseline. The QUALID is a proxy-rated quality of life in-
strument for people with dementia and consists of 11
items [18, 21]. Each items has 5 response options.
Summed scores range from 11 to 55 with lower scores
indicating better quality of life. The QUALID has good
psychometric properties in people with advanced de-
mentia [18, 22, 23]. The EQ-5D-3L contains five dimen-
sions (mobility, self-care, activities of daily living, pain/
discomfort and depression/anxiety) with 3 answer levels
(no problems to severe problems). Both the EQ-5D-3L
and QUALID were filled in by nursing staff. The EQ-
5D-3L health states were converted to utility scores
using the Dutch tariff, where 0 is anchored to death and
1 to full health (range − 0.30 to 1, where negative utilities
indicate that a health state is valued as worse than death)
[19]. Using the area under the curve method, QALYs
were calculated by multiplying the amount of time a
participant spent in a specific health state with the utility
score associated with that health state. Transitions be-
tween health states were linearly interpolated. The
GAIN measures family caregivers’ gains in dementia
caregiving [20]. The scale has 10 items that are scored
on a Likert scale from 0 (disagree a lot) to 4 (agree a
lot). Summed scores can range from 0 to 40, with higher
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scores indicating higher gains. The GAIN has good psy-
chometric properties [20].
Costs
Costs were measured from a societal perspective (sec-
ondary care costs, medication costs, family costs and
Namaste Care Family program costs) using question-
naires primarily based on a Dutch standardized data col-
lection tool for older nursing home residents, the
TOPIC-MDS [24] at 1, 3, 6, and 12months after base-
line. Additional questions on the costs of the Namaste
Care Family program were developed specifically for this
study. Medication use was assessed using medication
data from the nursing homes.
Healthcare utilization was valued using standard costs
from the Dutch costing guideline [25]. Medication costs
were valued using prices from the Royal Dutch Pharma-
cists Association [26]. Family costs included time spent
with the participant, administrative tasks for the partici-
pant, travel time and distance to visit the participant,
finding replacement for daily activities when visiting,
and lost productivity due to family caregivers’ absentee-
ism from work. The shadow price of these time invest-
ments is assumed to be equal to the tariff for cleaning
work. Lost productivity costs due to absenteeism from
work were calculated using gender-specific income
values of the Dutch population.
The Namaste Care Family program costs were esti-
mated using a bottom-up micro-costing approach, which
included costs of supplies for the intervention, any
change (increase or decrease) in nursing staff time as
well as hiring extra nursing staff, and family and volun-
teer time investments. Costs related to supplies and
other investments, as well as actual costs of donated
items, were collected by asking the participating nursing
homes to estimate the monetary value of supplies and
donations they received. Extra staff costs were estimated
using their hourly wage. All costs were expressed in
Euros for the year 2018 using consumer price indices
[27]. Discounting was not necessary, because follow-up
was restricted to 12months.
Statistical analysis
The cost-effectiveness analyses were conducted accord-
ing to the intention-to-treat principle. Missing data were
replaced using Multiple Imputation with Chained Equa-
tions (MICE) [28]. Cost and effect data were assumed to
be missing at random, which means that missing obser-
vations are explained by observed variables [29]. The im-
putation model included outcome variables and
predictor variables that either differed at baseline, were
related to missing data or were associated with the out-
come (see Table 2 for variables included in imputation
model). To account for the skewed distribution of cost
data, predictive mean matching was used in MICE [30].
The number of imputed datasets was increased until the
loss of efficiency was less than 5%, resulting in 10 imputed
datasets [30]. Each of the imputed datasets was analyzed
separately as described below. Results from the multiple
datasets were pooled using Rubin’s rules [31].
Multilevel regression models were used to estimate incre-
mental costs and effects between the treatment groups, while
accounting for the clustering of the data by allowing the inter-
cepts to vary across clusters (i.e. random intercepts model).
For costs and QALYs, a two-level structure was used where
nursing homes and participants represented the first and sec-
ond level, respectively. QALYs were adjusted for baseline util-
ity. For the difference in QUALID and GAIN, an additional
level accounted for repeated observations within persons (i.e.
scores at different time points). The differences in QUALID
and GAIN were additionally adjusted for confounders (see
Table 3 for list of confounders). Incremental Cost-
Effectiveness Ratios (ICERs) were calculated by dividing the
incremental costs by incremental effects. Bias-corrected boot-
strapping was used to estimate statistical uncertainty (2000
replications). Statistical uncertainty surrounding ICERs was il-
lustrated by plotting the bootstrapped cost-effect pairs on a
cost-effectiveness plane (CE plane). Cost-effectiveness accept-
ability curves (CEACs) were also estimated, which demon-
strate the probability that the Namaste Care Family program
is cost-effective compared to usual care for a range of different
ceiling ratios (i.e. the willingness-to-pay threshold for one
point effect extra) [32]. In the Netherlands, the generally used
willingness-to-pay threshold for healthcare interventions
ranges between 10,000 and 80,000 € per QALY gained [33].
For outcome measures such as the QUALID and GAIN, no
willingness-to-pay thresholds have been determined. Analyses
were performed in IBM SPSS Statistics 24® (IBM Corp.,
Armonk, NY, US), StataSE 14® (StataCorp LP, CollegeStation,
TX, US) and MLwiN® (University of Bristol, Bristol, UK) [34]
from within StataSE 14® [35]. To check the robustness of the
results, four sensitivity analyses were performed. First, the eco-
nomic evaluation was performed without adjustment for con-
founders (SA1). Second, it was performed from the healthcare
perspective (SA2), which included secondary care costs, medi-
cation costs, and Namaste Care Family program costs. Third,
clustering was ignored in the estimation of incremental costs
and effects (SA3). Finally, the economic evaluation was per-
formed using observed data, i.e. missing data was handled
using complete-case analysis (SA4).
Results
Population
Table 1 presents baseline characteristics for participants
in both groups. In total, 231 residents and their family
caregivers participated. Two participating nursing homes
randomized to the Namaste Care Family program
dropped out after 3 months and 6months, respectively.
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During follow-up, 60 (52%) participants in the interven-
tion group (n = 116) and 63 (55%) participants in the
usual care group (n = 115) had incomplete QALY data,
mostly due to death. For total societal costs, these fig-
ures were 44 (19%) and 49 (21%), respectively, which
was due to selective drop-out i.e. death of participant.
Supplementary Table 1 summarizes the probability of
having incomplete data for different baseline variables.
The probability of having incomplete data was twice as
high for participants that were born in the Netherlands
as compared to participants born outside the
Netherlands (odds ratio = 2.31, P = 0.034). The probabil-
ity of having incomplete data was also twice as high for
participants older than 80 years old as compared to par-
ticipants younger than 80 years (e.g. for QALY the odds
ratio = 2.11, P = 0.026). The number of family caregivers
that participated in the Namaste Care Family program
(n = 116) ranged from 33 (28%) family caregivers at one
month after baseline to 15 (13%) family caregivers at the
end of the trial. On average, family caregivers partici-
pated in 3.4 sessions per month.
Clinical outcomes (QUALID, GAIN and QALY)
Differences in QUALID and GAIN scores between the
Namaste Care Family program and usual care were
small and statistically not significant (Table 2). In
addition, the mean difference in QALYs between the
groups was not statistically significant (Table 2).
Costs
Mean total intervention costs amounted to 793 € per
participant (Table 2). Total healthcare costs were lower in
the Namaste Care Family program compared to usual
care, but this difference was not significant (− 1111 €,
95%CI: − 4071 to 1246). Medication costs were the main
contributor to this cost difference (− 1002 €, 95%CI: −
3971 to 1268). The difference in family costs between the
Namaste Care Family program and usual care was small
Table 1 Descriptives of the Namaste Care Family group and usual care group at baseline
Namaste Care Family program Usual care
n Mean (SD) / % (n) n Mean (SD) / % (n) P-valuec
Person with dementia
Age (years) 110 83.3 (8.1) 113 86.0 (6.9) .010*
Gender (% female) 116 71% (82) 114 75% (85) .510
% born in the Netherlands 108 82% (88) 110 94% (103) .006*
Educational level .374
None or primary school 106 43% (45) 110 35% (39)
(High school preparing for) technical/trade school 106 44% (47) 110 54% (59)
High school preparing for BSc or MSc 106 4% (4) 110 6% (6)
BSc or MSc degree 106 9% (10) 110 6% (6)
Dementia severitya 115 14.7 (4.8) 112 15.3 (4.2) .294
Utilityb (0–1) 115 0.46 (0.29) 112 0.44 (0.24) .460
Family caregivers
Age (years) 108 61.8 (11.1) 107 63.4 (11.4) .297
Gender (% female) 108 75% (81) 110 68% (75) .265
% born in the Netherlands 108 85% (92) 110 97% (107) .002*
Educational level .112
None or primary school 108 2% (2) 110 8% (9)
(High school preparing for) technical/trade school 108 52% (56) 110 52% (57)
High school preparing for BSc or MSc 108 8% (9) 110 11% (12)
BSc or MSc degree 108 38% (41) 110 29% (32)
Relation with person with dementia .578
Spouse / partner 109 22% (24) 112 17% (19)
Daughter or son (in law) 109 65% (71) 112 66% (74)
Other 109 14% (15) 112 15% (17)
a as measured by the Bedford Alzheimer Nursing Severity-Scale b as measured by the EQ-5D-3L c Baseline differences were tested using t-tests for continuous
variables and chi-square tests for categorical variables * P < .05, BSc Bachelor, MSc Master, SD Standard Deviation
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and not significant (7 €, 95%CI: − 288 to 303). The
difference in total societal costs was 311 € in favor of the
intervention group, which was not significant (95% CI: −
3397 to 2097).
Cost-effectiveness and cost-utility
For the QUALID, the ICER was 8919 (Table 3), meaning
that 1 point of improvement in QUALID score is
associated with a saving of 8919 € in the Namaste Care
Family group compared with the usual care group. Thus,
the Namaste Care Family program was dominant over
usual care. At ceiling ratios of 0, 10,000 and 20,000 € per
point of improvement on the QUALID, the probability
that the Namaste Care Family program is cost-effective
compared to usual care is 0.70, 0.75 and 0.73,
respectively (Fig. 1b).
For the GAIN, the ICER was − 7310 (Table 3), indicat-
ing that improvement of 1 point in GAIN score is associ-
ated with a saving of 7310 € in the Namaste Care Family
program as compared to the usual care group. Thus, the
Namaste Care Family program was dominant over usual
care. The CEAC (Fig. 1d) shows that the probability that
the Namaste Care Family program was cost-effective
compared to usual care is 0.70, 0.76 and 0.74 when the
ceiling ratio was set at 0, 10,000 and 20,000 € per point
improvement on the GAIN, respectively.
The cost-utility analysis resulted in an ICER of − 315,
671 (Table 3). This indicates that for each QALY that is
gained, 315,671 € is saved in the Namaste Family Care
program compared with the usual care group. Thus, the
Namaste Care Family program was dominant over usual
care. The CEAC (Fig. 1f) shows that the probability that
Table 2 Multiply imputed effects and costs for the Namaste program group (n = 116) and usual care group (n = 115) after 12
months
Outcomes Mean (SE) Mean difference (95%CI)c




Quality of Life in Late-Stage Dementia (QUALID) score (11–55)b Baseline 24.19 (0.80) 22.37 (0.71) −0.060 (− 0.42; 0.30)a
T1 24.95 (0.77) 22.87 (0.74)
T2 24.51 (0.79) 22.46 (0.73)
T3 23.88 (0.89) 21.85 (0.74)
T4 23.40 (2.25) 22.51 (1.04)
Gain in Alzheimer Care Instrument (GAIN) score (0–40) Baseline 24.94 (0.80) 22.77 (0.82) 0.033 (−0.24; 0.31)a
T1 24.96 (0.81) 22.60 (1.03)
T2 23.93 (1.02) 23.06 (0.93)
T3 22.09 (1.21) 23.32 (0.99)
T4 26.26 (1.74) 23.62 (1.37)
Quality Adjusted Life Year (QALY) (0–1) 0.40 (0.026) 0.39 (0.022) 0.015 (−0.058; 0.088)
Healthcare costs
Secondary care 251 (110) 361 (151) −110 (− 529; 215)
Medication 5430 (777) 6432 (1047) − 1002 (− 3971; 1268)
Total healthcare costs 5682 (802) 6793 (1065) − 1111 (− 4071; 1246)
Donations 105 (16) 0 (0) 105 (76; 139)
Structural 211 (29) 0 (0) 211 (163; 276)
Extra staff 477 (89) 0 (0) 477 (325; 681)
Total intervention costs 793 (110) 0 (0) 793 (602; 1036)
Non-healthcare costs
Family 698 (121) 691 (131) 7 (− 288; 303)
Total societal costs 7173 (852) 7484 (1087) − 311 (− 3397; 2097)
aOverall effect over time corrected for score at baseline
bA lower QUALID score indicates improved health. A higher QUALID score indicates worse health
cUncertainty around cost differences estimated using the non-parametric bootstrap
SE standard error, 95%CI 95% confidence interval
Multiple imputation model consisted of variables that differed at baseline, were related to missing data or were associated with the outcome: age of family
caregiver, age of person with dementia, country of birth of person with dementia, country of birth of family caregiver, gender person with dementia, gender of
family caregiver, relation of family caregiver with person with dementia, marital status of person with dementia, highest completed education of person with
dementia and having a payed job for the family caregiver
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the Namaste Care Family program was cost-effective
compared to usual care is 0.70, 0.70 and 0.69 when the
ceiling ratio was set at 0, 10,000 and 20,000 € per
additional QALY, respectively.
Sensitivity analysis
Results of the unadjusted analyses (SA1) were somewhat
different for the GAIN score and QALY. For GAIN, the
incremental effect decreased from 0.075 to 0.033, result-
ing in the ICER being doubled from − 7310 to − 16,913,
meaning that improvement of 1 point on the GAIN
score is associated with a saving of 16,913 €. For QALY,
the incremental effect increased, which resulted in a
smaller ICER, i.e. -36,744. The cost-effectiveness ana-
lyses from a healthcare perspective (SA2) were compar-
able to the main analyses (Table 3). Ignoring clustering
in the economic evaluation (SA3), resulted in a smaller
cost saving of the Namaste Care Family program as
compared to usual care than in the main analysis. As a
consequence, the probability of cost-effectiveness at 0 €
per additional unit of effect (0.58) was lower than in the
main analysis (0.70). The complete-case analysis (SA4)
had a large impact on the outcomes. The difference in
societal costs became positive (214 €, 95%CI: − 7863 to
5630), the difference in QUALID score decreased, the
difference in GAIN score became negative and the
difference in QALY increased. Figure 2 graphically
illustrates the sensitivity analysis in terms of the prob-
ability of cost-effectiveness for QALYs.
Discussion
Main findings
We found no statistically significant differences in costs
and clinical outcomes between the Namaste Care Family
program and usual care, although overall clinical out-
comes improved and costs were lower. When considering
statistical uncertainty, the probability of the Namaste Care
Family program being cost-effective compared to usual
care at a ceiling ratio of 0 € per additional unit of effect is
0.70. Based on these results, the Namaste Care Family
Table 3 Results of the cost-effectiveness analysis, cost-utility analysis and sensitivity analyses
Outcome ΔC (95% CI) d ΔE (95% CI) ICER CE plane
NE SE SW NW
Main analysis: Societal perspective
Quality of Life in Late-Stage Dementia (QUALID) score (11–55) − 552 (− 2920; 1903) −0.062 (− 0.40; 0.28) a,b 8919 21% 49% 21% 9%
Gain in Alzheimer Care Instrument (GAIN) score (0–40) − 552 (− 2920; 1903) 0.075 (− 0.20; 0.35) a,c −7310 20% 48%% 22% 10%
QALYs (0–1) −552 (− 2920; 1903) 0.0017 (− 0.059; 0.063) −315,671 17% 35% 35% 13%
SA1: Unadjusted analysis
Quality of Life in Late-Stage Dementia (QUALID) score (11–55) −552 (− 2920; 1903) − 0.060 (− 0.40; 0.28)a 9158 21% 49% 21% 9%
Gain in Alzheimer Care Instrument (GAIN) score (0–40) −552 (− 2920; 1903) 0.033 (− 0.26; 0.32)a −16,913 16% 37% 33% 14%
QALYs (0–1) −552 (− 2920; 1903) 0.015 (− 0.058; 0.088) − 36,774 20% 46% 24% 10%
SA 2: Healthcare perspective
Quality of Life in Late-Stage Dementia (QUALID) score (11–55) − 548 (− 2805; 1927) − 0.062 (− 0.40; 0.28) a,b 8861 19% 50% 21% 9%
Gain in Alzheimer Care Instrument (GAIN) score (0–40) − 548 (− 2805; 1927) 0.075 (− 0.20; 0.35) a,c − 7263 19% 49% 23% 9%
QALYs (0–1) − 548 (− 2805; 1927) 0.0017 (− 0.059; 0.063) − 313,640 16% 36% 35% 13%
SA 3: Ignore clustering of data
Quality of Life in Late-Stage Dementia (QUALID) score (11–55) − 311 (− 3340; 2227) 0.15 (− 0.27; 0.47) a,b − 2065 7% 10% 49% 34%
Gain in Alzheimer Care Instrument (GAIN) score (0–40) − 311 (− 3340; 2227) 0.18 (− 0.12; 0.48) a,c − 1714 37% 51% 7% 5%
QALYs (0–1) − 311 (− 3340; 2227) 0.0018 (− 0.058; 0.062) − 169,209 22% 32% 26% 20%
SA 4: Complete-case analysis
Quality of Life in Late-Stage Dementia (QUALID) score (11–55) 214 (− 7863; 5630) − 0.20 (− 0.53; 0.12) a,b − 1059 46% 45% 5% 4%
Gain in Alzheimer Care Instrument (GAIN) score (0–40) 214 (− 7863; 5630) − 0.15 (− 0.44; 0.15) a,c − 1469 2% 13% 37% 48%
QALYs (0–1) 214 (− 7863; 5630) 0.026 (− 0.12; 0.072) − 8118 13% 13% 37% 37%
aOverall effect over time corrected for score at baseline
bQUALID was adjusted for age person with dementia, gender of person with dementia, education of person with dementia. A lower score indicates improved
health. A higher score indicates decreases health
cGAIN was adjusted for age family caregiver, gender family caregiver, education family caregiver, relationship between person with dementia and family caregiver
d Uncertainty around cost differences estimated using the non-parametric bootstrap
CE plane cost-effectiveness plane, ICER incremental cost-effectiveness ratio, SA sensitivity analysis, 95%CI 95% confidence interval
CE-plane quadrants:
NE North-east quadrant indicates higher costs and improved health for Namaste in comparison with usual care, NW North-west quadrant indicates higher costs
and worse health, SE South-east quadrant indicates lower costs and improved health, SW South-west quadrant indicates lower costs and worse health
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program is dominant over and cost-effective compared to
usual care, however, some uncertainty is present which
indicates that these results should be interpreted with
caution.
Interpretation of findings and comparison with literature
Although not statistically significant, the direction of the
outcomes of the cost-effectiveness analyses of the Namaste
Care Family program is in line with previously published
studies that showed that Namaste Care can improve quality
of life nursing home residents with advanced dementia in
the United Kingdom [11, 16].
In line with previous studies investigating the imple-
mentation of the Namaste Care program [11, 12], no
statistically significant differences in costs between the
Namaste Care Family program and usual care were found.
However, a recent costing study that developed a full cost
model (i.e. mapping all relevant individual cost compo-
nents based on resources needed for the intervention) for
Namaste Care in the United Kingdom, estimated higher
staff costs for Namaste Care as compared to usual care
than in the current study. In that study, staff costs were
the largest contributor to total Namaste Care costs [13].
In the current economic evaluation, the intervention costs
amounted to 793 €, including staff costs of 477 € which is
relatively low compared to the estimated costs in the UK
cost model [13]. A possible explanation is that the UK
study also included capital costs (e.g. costs related to
Namaste room hire in care homes), while in the current
economic evaluation these type of costs were assumed to
be included in the standard costs to estimate the interven-
tion costs [25]. Also, more involvement of family care-
givers may reduce costs of Namaste Care, and, thereby,
increase the efficiency of the program. In the current
study, the involvement of family caregivers was only mod-
est. It is important to consider that involvement of family
caregivers could increase the burden and strain on family
caregivers, which adversely impacts the health of family
caregivers [36, 37]. However, it can also decrease burden
and provide positive experiences for family caregivers. In
Fig. 1 Cost-effectiveness planes and cost-effectiveness acceptability curves
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the current study the burden on family caregivers was not
increased [38].
Strengths and limitations
A strength of the current economic evaluation is the prag-
matic design, meaning that actual practice is resembled as
much as possible, which increases the generalizability of the
results. Another strength relates to the societal perspective
used, meaning that all relevant costs were taken into account
regardless of who pays for them. This enables the identifica-
tion of potential cost shifts between sectors, for example
from the healthcare system to the patient and his/her family.
In addition, clustering at the level of nursing homes was
accounted for in the analyses. For the QUALID and GAIN,
an additional level was added for the repeated observations
over time. Clustering of data is frequently ignored in cost-
effectiveness analyses alongside cluster-randomized con-
trolled trials [39]. Appropriately accounting for clustering of
data (main analysis) versus ignoring clustering of data (SA3)
shows that ignoring clustering can affect the estimates of an
economic evaluation substantially, thereby potentially chan-
ging the conclusion of an economic evaluation.
There are also a number of limitations of the current
study. In residents with dementia, the use of proxies is a
common approach to overcome difficulties associated
with the assessment of outcomes. Some argue that quality
of life is difficult to be estimated by proxies [40]. However,
a number of studies [41, 42] suggest that information from
proxy raters are sensitive to actual changes in quality of
life, especially when the proxy is a family caregiver. A re-
cent systematic review found no significant difference in
quality of life scores between family caregivers and staff
proxy ratings for nursing home residents with dementia
[43]. Although the EQ-5D is the preferred instrument to
estimate utility scores in economic evaluations, it may not
capture all important aspects of psychosocial care for ad-
vanced dementia [44–46]. Therefore, specific dementia
outcomes, i.e. the QUALID and GAIN for family care-
givers of persons with dementia, were also assessed in this
study [46]. Last, a considerable amount of data was miss-
ing, which was accounted for by using multiple imput-
ation; this is considered the most appropriate method to
deal with missing data in economic evaluations [47].
Conclusion
This study showed that the Namaste Care Family program
is dominant over usual care, primarily due to cost savings.
Therefore, the Namaste Care Family program can be con-
sidered cost-effective compared to usual care. However,
there is a considerable amount of statistical uncertainty sur-
rounding the results. Therefore, these results should be
interpreted with caution. Future research should investigate
whether the results can be confirmed in different settings.
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